Glioblastomas with an oligodendroglial component: A pathological and molecular study

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 9, 2001, Pages 863-871

  He, J ^a   Mokhtari, K ^b   Sanson, M ^a,b   Marie, Y ^a   Kujas, M ^b   Huguet, S ^a   Leuraud, P ^a   Capelle, L ^b   Delattre, J Y ^a,b   Poirier, J ^b   Hoang Xuan, Khê ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

10; 19q; 1p; EGFR; Glioblastoma; Oligodendroglioma; P16

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC DISORDER; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR BIOLOGY; NEUROPATHOLOGY; OLIGODENDROGLIA; PRIORITY JOURNAL;

EID: 0034830489     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.9.863     Document Type: Article

References (43)

1. Intratumoral histologic heterogeneity of gliomas. A quantitative study
2. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
3. Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy
4. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
5. Growth factors, glia and gliomas
6. Revising the world health organization (WHO) blue book. Histological typing of tumours of the central nervous system
7. Association of p53 mutations with short survival in colorectal cancer
8. Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations
9. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas
10. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue
11. A molecular genetic model of astrocytoma histopathology
12. Progression as exemplified by human astrocytic tumors
13. Molecular pathogenesis of malignant gliomas
14. p53 mutations in non astrocytic human brain tumors
15. Genetic alterations associated with the evolution and progression of astrocytic brain tumors
16. Epidermal growth factor receptor expression in oligodendroglial tumors
17. Infrequent alterations of the p15, p16, CDK4 and cyclinD1 genes in non astrocytic human brain tumors
18. pTEN mutations in gliomas and glioneural tumors
19. Allelic deletion analyses of MMAC/pTEN and DMBT1 loci in gliomas: Relationship to prognostic significance
20. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter
21. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
22. Molecular genetic evidence of subtypes of oligoastrocytomas
23. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
24. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas
25. Deletion mapping of chromosome 19 in human gliomas
26. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors
27. Shared allelic losses on chromosome 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
28. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors
29. A transcript map of the chromosome 19p-arm glioma tumor suppressor region
30. pTEN (MMAC1) mutations are frequent in primary glioblastoma (de novo) but not in secondary glioblastomas
31. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
32. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
33. Chemotherapy for anaplastic oligodendroglioma
34. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
35. Genes for epidermal growth factor, transforming growth factor alpha and epidermal growth factor and their expression in human gliomas in vivo
36. Alterations of the TP53 gene in human gliomas
37. CDKN2 (p16/MST1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
38. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization
39. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
40. Long survival and therapeutic responses in patients with histologically disparate high grade gliomas demonstrating chromosome 1p loss
41. Molecular subtypes of anaplastic oligodendrogliomas: Implications for patient management at diagnosis